GVBP ... GENova Biotherapeutics, Inc

[Aufan 1983]

GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9/10/2009 4:00:00 PM ET

NEW YORK, Sept. 10 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, is pleased to announce that it is in the process of acquiring three promising new drug target patents that could generate over a billion dollar in royalty fees in the mid to long term.

Aaron Whiteman, CEO for GENova says, "Following a rigorous evaluation phase, we have selected three potential blockbuster drug target patents for acquisition, and we look forward to integrating them into our IP portfolio." The acquisition targets still subject to due diligence and contract would include both preclinical and clinical drugs that show promising potential in the major markets of anti-cancer and anti-infective drugs.

GENova will announce details of these new biological products in the coming weeks.


GENova's Current IP Portfolio


The three new patents would join GENova's current proprietary IP products --tetanolic acid (for breast cancer) and prostaganin (for prostate cancer)-- in the company's growing IP portfolio.

Known as an alpha hydroxyoleic acid, tetanolic acid is a form of a lipid that has the demonstrated ability to affect the growth and proliferation of cells. Seeing that cancer is characterised as a normal proliferation of cells, these lipids can potentially prevent cancer spread. Preliminary tests in mice have shown that the protein can prevent the growth and spread of cancer in mice. GENova's Tetanolic acid is therefore a prime candidate for development of an anti-cancer medicament in humans. The breast cancer therapeutics market is expected to grow from its current level of US$5.9 billion(EUR5 million) to $11.5 billion by 2011, with a compound annual growth rate (CAGR) of 9.8 per cent (Frost Sullivan).

GENova's proprietary peptide for prostate cancer, Prostaganin, demonstrates an ability to completely inhibit the growth of prostate tumour xenografts. Furthermore, it can markedly reduce the secretion of the prostate-specific antigen (PSA), a biomarker widely known to be indicative of this malignancy. Therefore, GENova's Prostaganin is another candidate with blockbuster potential for development of an anti-cancer medicament for treatment of humans. The current market for prostate cancer therapies amounts to US$1.5 billion (Drugresearcher.com). But as newer and more innovative therapies are applied, the market is set to experience double digit growth.

[Volatile22]

Wow this should fly. Ive had it on the watch list since Gdog brought it to my attention the other day. Its been making nice gains since then. Very nice.

[Aufan 1983]

MORE NEWS!!!!!!!!!!!!

New stem cell identification technology could cure breast cancer
Press Release Source: GENova Biotherapeutics, Inc.
On Friday September 11, 2009, 6:00 am EDT

NEW YORK, Sept. 11 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB - News) - GENova Biotherapeutics, Inc., ("GENova"), released important information about its innovative method for destroying breast cancer cells, using stem cell technology.

GENova's approach is based on cutting-edge technology that enables us to identify the protein expression in the original cancer stem cells that give rise to tumors. This ability to identify the molecular markers of these cells is an important first step in developing new and superior cancer cures, says John Savin, VP for GENova. "By recognizing the existence of cancer stem cells, we have taken a great step towards understanding this complex disease. Now that we know how to identify the unique characteristics of these stem cells, we can develop cell-specific therapies that can eradicate them --and thus neutralize breast cancer right at the source."

The key behind GENova's biotechnology is tracing cancer cells to their origin, the very stem cells from where the first malignant cell arose. Now that they are identifiable, scientists are developing tailor-made proteins that are programmed to destroy cancerous cells, whilst leaving the healthy cells intact. GENova has targeted these bio-engineered proteins for acquisition into its growing anti-cancer drug pipeline.

In the future, this technology will also enable us to identify healthy stem cells and then develop, inject, and nurture them in such a way that they can overcome the malignant cells. Eventually, healthy stem cells will overcome the sick cells, leaving the patient cured. This novel method for treating breast cancer is far superior to existing treatments, and is the underpinning of GENova's IP (Intellectual Property) portfolio.

Development of this important biotechnology would mean a new cure for cancer, rendering disfiguring mastectomies and harmful radiation therapies obsolete

[WeatherCat]

Made a few bucks on this one today...Thanks for the tip Aufan!!! There was massive volume today but gotta be careful here in my opinion since these guys were a travel company (scratching head) just a few months ago and now they have a cure for breast cancer?? Check out the latest 10K for all the details...

Summary of GENOVA BIOTHERAPEUTICS INC. - Yahoo! Finance

[WeatherCat]

FWIW here is some info on these guys...

Technical Trading Overview for Genova Biotherapeutics Inc. (GVBP)
September 8, 2009
Genova Biotherapeutics Inc. (OTCBB: GVBP)

Genova Biotherapeutics Inc. (GVBP) is a development stage company engaged in the discovery, development and commercialization of new bioscience technologies that fight infectious disease and cancer, particularly breast and prostate cancer. GVBP already possesses two proprietary anti-tumor drug targets and is in the process of acquiring three more patents. The Company’s business strategy is to leverage cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and to then license these patented drug product candidates to major pharmaceutical and biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex and Biogen Idec.

Prior to being a biotechnological drug development company, GVBP was known as Kinder Travel Inc., a travel agency offering a full range of travel services including corporate travel, vacations, cruise holidays and group tours. On April 24, the Company changed its name to accurately reflect its new business activities, and subsequently disposed of its travel related business assets on July 21, 2009.

Share Statistics

(08-Sept-09)

2007
2008
%

Chg
Q2 ‘08
Q2 ‘09
% Chg

Symbol
GVBP
Revenue, CND$Mn
0.2
0.2
n/a
0.1
0.1
n/a

Current price
$0.16
Gross marg.
n/a
55.87%

[greencat]

Real nice move to the upside this morning. Currently 37%. Nice call..

[LikesTrading]

Ah, a friend pointed GVBP out to me last week.
Sadly, I didn't make a move then.

[WeatherCat]

Originally Posted by greencat

Real nice move to the upside this morning. Currently 37%. Nice call..

Greencat,

Do you think this has legs to keep running??? In other words, does the chart look like the pps will hold up?? I wonder if this is going to keep running or if the car is about outta gas!!!

[greencat]

Originally Posted by WeatherCat

Greencat,

Do you think this has legs to keep running??? In other words, does the chart look like the pps will hold up?? I wonder if this is going to keep running or if the car is about outta gas!!!

Sure it can keep going. Its just not my kind of play right now. A some point sellers come in and take profit. I will wait for a pullback. Just to scary for me to enter right now.

[Aufan 1983]

Originally Posted by greencat

Sure it can keep going. Its just not my kind of play right now. A some point sellers come in and take profit. I will wait for a pullback. Just to scary for me to enter right now.

Yeah, it has taken off the past couple of days. I'm still holding 5k from .17 so smiling big but you are right on target about profit takers. I think it could gap tomorrow and then pullback...... but just a guess